<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02674204</url>
  </required_header>
  <id_info>
    <org_study_id>IIT2015-12-Goodman-STOP</org_study_id>
    <nct_id>NCT02674204</nct_id>
  </id_info>
  <brief_title>STOP Heart Disease in Breast Cancer Survivors Trial</brief_title>
  <acronym>STOP</acronym>
  <official_title>Statin Therapy Operates to Prevent (STOP) Heart Disease in Breast Cancer Survivors Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>California Breast Cancer Research Program</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cedars-Sinai Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to to examine the effects of atorvastatin, a type of statin, on
      changes to the heart among women undergoing breast cancer treatment. Atorvastatin may reduce
      or eliminate the harmful effects of chemotherapy treatment to the heart tissue of breast
      cancer patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a placebo-controlled study. It will compare the effects of atorvastatin against the
      effects of a placebo (an inactive substance, such as, a sugar pill) on changes to the heart
      before and during breast cancer treatment. Participants will be in the study for
      approximately a year and a half, and the study will enroll up to 60 patients. During that
      time, there will be six visits that may coincide with standard of care visits. Participants
      will also receive telephone calls from study staff during the study intervention and a
      follow-up phase to check-in with them.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Closed due to low accrual
  </why_stopped>
  <start_date type="Actual">May 5, 2016</start_date>
  <completion_date type="Actual">May 25, 2018</completion_date>
  <primary_completion_date type="Actual">May 25, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Global Circumferential Strain (GCS) Measured by Cardiac MRI (CMRI)</measure>
    <time_frame>baseline to 12 months post initiation of statin intervention</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Global Longitudinal Strain as Measured by CMRI</measure>
    <time_frame>Baseline to 12 months of follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Peak Left Ventricular Twist as Measured by CMRI</measure>
    <time_frame>Baseline to 12 months of follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Peak Left Ventricular Torsion as Measured by CMRI</measure>
    <time_frame>Baseline to 12 months of follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Left Ventricular Untwisting Rate as Measured by CMRI</measure>
    <time_frame>Baseline to 12 months of follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Left Ventricular Ejection Fraction as Measured by CMRI</measure>
    <time_frame>Baseline to 12 months of follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Left Ventricular End Diastolic Volume as Measured by CMRI</measure>
    <time_frame>Baseline to 12 months of follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Left Ventricular End Systolic Volume as Measured by CMRI</measure>
    <time_frame>Baseline to 12 months of follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cardiac Output as Measured by CMRI</measure>
    <time_frame>Baseline to 12 months of follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Left Ventricular Mass as Measured by CMRI</measure>
    <time_frame>Baseline to 12 months of follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Left Ventricular Concentricity as Measured by CMRI</measure>
    <time_frame>Baseline to 12 months of follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Native T1 as Measured by CMRI</measure>
    <time_frame>Baseline to 12 months of follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Post Contrast T1 as Measured by CMRI</measure>
    <time_frame>Baseline to 12 months of follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Extracellular Volume as Measured by CMRI</measure>
    <time_frame>Baseline to 12 months of follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Native T2 as Measured by CMRI</measure>
    <time_frame>Baseline to 12 months of follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Heart Disease</condition>
  <condition>Cardiotoxicity</condition>
  <condition>Myocardial Dysfunction</condition>
  <arm_group>
    <arm_group_label>Study Agent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One atorvastatin 20 mg oral capsule per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One matching placebo daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Atorvastatin calcium, a synthetic lipid-lowering agent, is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, an early and rate-limiting step in cholesterol biosynthesis.</description>
    <arm_group_label>Study Agent</arm_group_label>
    <other_name>Lipitor</other_name>
    <other_name>Atorvastatin calcium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A substance that has no therapeutic effect, and will be used as a control in testing the study agent.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patients with newly diagnosed stage 1-3 breast cancer

          -  Histologically confirmed HER2, ER, and PR status

          -  Recommended to undergo trastuzumab treatment, with or without anthracycline. Patients
             will be eligible for up to 3 weeks after starting treatment.

          -  Age minimum 18 years

          -  Able and willing to read, understand, and sign an informed consent form (ICF) and
             medical release form

          -  Willing and able to comply with trial protocol and follow-up

          -  ECOG performance status 0-1 (Karnofsky ≥ 70%)

        Exclusion Criteria:

          -  Prior use of statin medication within the past year

          -  Not using statin medication but is eligible for statin therapy based on the 2013
             ACC/AHA guidelines (LDL cholesterol &gt;190, or LDL &lt;190 and ASCVD risk &gt;7.5%;
             http://tools.acc.org/ASCVD-Risk-Estimator/) and is &gt; 50 years old; or is eligible for
             statin therapy based on the 2013 ACC/AHA guidelines and is 40-50 years old and wishes
             to be placed on statin therapy

          -  History of adverse effects, intolerance, or allergic reactions attributed to statin
             medication

          -  Current use of gemfibrozil, cyclosporine, clarithromycin, itraconazole, erythromycin,
             the hepatitis C protease inhibitor telaprevir, HIV protease inhibitors, colchicine, or
             red yeast rice

          -  Current use of any other investigational agent

          -  Pregnant or intention to get pregnant during the next 18 months. Pregnant women are
             excluded from this study because atorvastatin is a lipid-lowering agent with the
             potential for teratogenic or abortifacient effects, and MRI is contraindicated in
             pregnant women.

          -  History of diabetes, severe lung disease, renal disease (creatinine &gt; 1.8 mg/dL or
             CrCl ≤ 50 mL/min), or hepatic disease (AST and ALT &gt; 3 times upper normal limits)

          -  Abnormal baseline echocardiogram or cardiac MRI (detection of congenital heart
             disease; ischemic heart disease; moderate or severe valvular heart disease;
             cardiomyopathy; EF &lt; 55%)

          -  Previously known or diagnosed heart disease (e.g. congenital; valvular; coronary
             artery disease; history of myocardial infarction or acute coronary syndrome;
             cardiomyopathy, including infiltrative, hypertensive, hypertrophic, dilated,
             constrictive pericarditis, or other cardiomyopathy)

          -  Left ventricular dysfunction (EF &lt; 55%)

          -  Prior non-cardiac illness with an estimated life expectancy &lt; 4 years

          -  Known active infection with HIV

          -  Allergy or contraindication to MRI testing, including claustrophobia, metallic parts
             in body the prohibiting MRI, prior gadolinium contrast reaction, or uncontrolled
             moderate hypertension (sitting blood pressure &gt;160/95 mm Hg with measurements recorded
             on at least 2 occasions).

          -  Has metallic breast expanders in place at the time of screening

          -  Concurrent illness which in the opinion of the investigators would compromise either
             the patient or the integrity of the data
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Goodman, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinal Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>January 21, 2016</study_first_submitted>
  <study_first_submitted_qc>February 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2016</study_first_posted>
  <results_first_submitted>March 25, 2019</results_first_submitted>
  <results_first_submitted_qc>April 9, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 30, 2019</results_first_posted>
  <last_update_submitted>May 1, 2019</last_update_submitted>
  <last_update_submitted_qc>May 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cedars-Sinai Medical Center</investigator_affiliation>
    <investigator_full_name>Marc Goodman</investigator_full_name>
    <investigator_title>Professor and Director, Cancer Prevention &amp; Control - Department, Cancer Institute</investigator_title>
  </responsible_party>
  <keyword>Statin therapy</keyword>
  <keyword>trastuzumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Cardiotoxicity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 29, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/04/NCT02674204/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 1, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/04/NCT02674204/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Study Agent</title>
          <description>One atorvastatin 20 mg oral capsule per day
Atorvastatin: Atorvastatin calcium, a synthetic lipid-lowering agent, is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, an early and rate-limiting step in cholesterol biosynthesis.</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>One matching placebo daily
Placebo: A substance that has no therapeutic effect, and will be used as a control in testing the study agent.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Study Agent</title>
          <description>One atorvastatin 20 mg oral capsule per day
Atorvastatin: Atorvastatin calcium, a synthetic lipid-lowering agent, is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, an early and rate-limiting step in cholesterol biosynthesis.</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>One matching placebo daily
Placebo: A substance that has no therapeutic effect, and will be used as a control in testing the study agent.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Global Circumferential Strain (GCS) Measured by Cardiac MRI (CMRI)</title>
        <time_frame>baseline to 12 months post initiation of statin intervention</time_frame>
        <population>As accrual fell well below target, change in global circumferential strain (GCS) measured by Cardiac MRI (CMRI) was not calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Agent</title>
            <description>One atorvastatin 20 mg oral capsule per day
Atorvastatin: Atorvastatin calcium, a synthetic lipid-lowering agent, is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, an early and rate-limiting step in cholesterol biosynthesis.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>One matching placebo daily
Placebo: A substance that has no therapeutic effect, and will be used as a control in testing the study agent.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Global Circumferential Strain (GCS) Measured by Cardiac MRI (CMRI)</title>
          <population>As accrual fell well below target, change in global circumferential strain (GCS) measured by Cardiac MRI (CMRI) was not calculated.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Global Longitudinal Strain as Measured by CMRI</title>
        <time_frame>Baseline to 12 months of follow-up</time_frame>
        <population>As accrual fell well below target, change in global longitudinal strain as measured by CMRI was not calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Agent</title>
            <description>One atorvastatin 20 mg oral capsule per day
Atorvastatin: Atorvastatin calcium, a synthetic lipid-lowering agent, is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, an early and rate-limiting step in cholesterol biosynthesis.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>One matching placebo daily
Placebo: A substance that has no therapeutic effect, and will be used as a control in testing the study agent.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Global Longitudinal Strain as Measured by CMRI</title>
          <population>As accrual fell well below target, change in global longitudinal strain as measured by CMRI was not calculated.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Peak Left Ventricular Twist as Measured by CMRI</title>
        <time_frame>Baseline to 12 months of follow-up</time_frame>
        <population>As accrual fell well below target, change in peak left ventricular twist as measured by CMRI was not calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Agent</title>
            <description>One atorvastatin 20 mg oral capsule per day
Atorvastatin: Atorvastatin calcium, a synthetic lipid-lowering agent, is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, an early and rate-limiting step in cholesterol biosynthesis.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>One matching placebo daily
Placebo: A substance that has no therapeutic effect, and will be used as a control in testing the study agent.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Peak Left Ventricular Twist as Measured by CMRI</title>
          <population>As accrual fell well below target, change in peak left ventricular twist as measured by CMRI was not calculated.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Peak Left Ventricular Torsion as Measured by CMRI</title>
        <time_frame>Baseline to 12 months of follow-up</time_frame>
        <population>As accrual fell well below target, change in peak left ventricular torsion as measured by CMRI was not calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Agent</title>
            <description>One atorvastatin 20 mg oral capsule per day
Atorvastatin: Atorvastatin calcium, a synthetic lipid-lowering agent, is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, an early and rate-limiting step in cholesterol biosynthesis.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>One matching placebo daily
Placebo: A substance that has no therapeutic effect, and will be used as a control in testing the study agent.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Peak Left Ventricular Torsion as Measured by CMRI</title>
          <population>As accrual fell well below target, change in peak left ventricular torsion as measured by CMRI was not calculated.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Left Ventricular Untwisting Rate as Measured by CMRI</title>
        <time_frame>Baseline to 12 months of follow-up</time_frame>
        <population>As accrual fell well below target, change in left ventricular untwisting rate as measured by CMRI was not calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Agent</title>
            <description>One atorvastatin 20 mg oral capsule per day
Atorvastatin: Atorvastatin calcium, a synthetic lipid-lowering agent, is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, an early and rate-limiting step in cholesterol biosynthesis.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>One matching placebo daily
Placebo: A substance that has no therapeutic effect, and will be used as a control in testing the study agent.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Left Ventricular Untwisting Rate as Measured by CMRI</title>
          <population>As accrual fell well below target, change in left ventricular untwisting rate as measured by CMRI was not calculated.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Left Ventricular Ejection Fraction as Measured by CMRI</title>
        <time_frame>Baseline to 12 months of follow-up</time_frame>
        <population>As accrual fell well below target, change in left ventricular ejection fraction as measured by CMRI was not calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Agent</title>
            <description>One atorvastatin 20 mg oral capsule per day
Atorvastatin: Atorvastatin calcium, a synthetic lipid-lowering agent, is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, an early and rate-limiting step in cholesterol biosynthesis.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>One matching placebo daily
Placebo: A substance that has no therapeutic effect, and will be used as a control in testing the study agent.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Left Ventricular Ejection Fraction as Measured by CMRI</title>
          <population>As accrual fell well below target, change in left ventricular ejection fraction as measured by CMRI was not calculated.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Left Ventricular End Diastolic Volume as Measured by CMRI</title>
        <time_frame>Baseline to 12 months of follow-up</time_frame>
        <population>As accrual fell well below target, change in left ventricular end diastolic volume as measured by CMRI was not calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Agent</title>
            <description>One atorvastatin 20 mg oral capsule per day
Atorvastatin: Atorvastatin calcium, a synthetic lipid-lowering agent, is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, an early and rate-limiting step in cholesterol biosynthesis.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>One matching placebo daily
Placebo: A substance that has no therapeutic effect, and will be used as a control in testing the study agent.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Left Ventricular End Diastolic Volume as Measured by CMRI</title>
          <population>As accrual fell well below target, change in left ventricular end diastolic volume as measured by CMRI was not calculated.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Left Ventricular End Systolic Volume as Measured by CMRI</title>
        <time_frame>Baseline to 12 months of follow-up</time_frame>
        <population>As accrual fell well below target, change in left ventricular end systolic volume as measured by CMRI was not calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Agent</title>
            <description>One atorvastatin 20 mg oral capsule per day
Atorvastatin: Atorvastatin calcium, a synthetic lipid-lowering agent, is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, an early and rate-limiting step in cholesterol biosynthesis.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>One matching placebo daily
Placebo: A substance that has no therapeutic effect, and will be used as a control in testing the study agent.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Left Ventricular End Systolic Volume as Measured by CMRI</title>
          <population>As accrual fell well below target, change in left ventricular end systolic volume as measured by CMRI was not calculated.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Cardiac Output as Measured by CMRI</title>
        <time_frame>Baseline to 12 months of follow-up</time_frame>
        <population>As accrual fell well below target, change in cardiac output as measured by CMRI was not calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Agent</title>
            <description>One atorvastatin 20 mg oral capsule per day
Atorvastatin: Atorvastatin calcium, a synthetic lipid-lowering agent, is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, an early and rate-limiting step in cholesterol biosynthesis.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>One matching placebo daily
Placebo: A substance that has no therapeutic effect, and will be used as a control in testing the study agent.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cardiac Output as Measured by CMRI</title>
          <population>As accrual fell well below target, change in cardiac output as measured by CMRI was not calculated.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Left Ventricular Mass as Measured by CMRI</title>
        <time_frame>Baseline to 12 months of follow-up</time_frame>
        <population>As accrual fell well below target, change in left ventricular mass as measured by CMRI was not calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Agent</title>
            <description>One atorvastatin 20 mg oral capsule per day
Atorvastatin: Atorvastatin calcium, a synthetic lipid-lowering agent, is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, an early and rate-limiting step in cholesterol biosynthesis.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>One matching placebo daily
Placebo: A substance that has no therapeutic effect, and will be used as a control in testing the study agent.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Left Ventricular Mass as Measured by CMRI</title>
          <population>As accrual fell well below target, change in left ventricular mass as measured by CMRI was not calculated.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Left Ventricular Concentricity as Measured by CMRI</title>
        <time_frame>Baseline to 12 months of follow-up</time_frame>
        <population>As accrual fell well below target, change in left ventricular concentricity as measured by CMRI was not calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Agent</title>
            <description>One atorvastatin 20 mg oral capsule per day
Atorvastatin: Atorvastatin calcium, a synthetic lipid-lowering agent, is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, an early and rate-limiting step in cholesterol biosynthesis.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>One matching placebo daily
Placebo: A substance that has no therapeutic effect, and will be used as a control in testing the study agent.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Left Ventricular Concentricity as Measured by CMRI</title>
          <population>As accrual fell well below target, change in left ventricular concentricity as measured by CMRI was not calculated.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Native T1 as Measured by CMRI</title>
        <time_frame>Baseline to 12 months of follow-up</time_frame>
        <population>As accrual fell well below target, change in native T1 as measured by CMRI was not calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Agent</title>
            <description>One atorvastatin 20 mg oral capsule per day
Atorvastatin: Atorvastatin calcium, a synthetic lipid-lowering agent, is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, an early and rate-limiting step in cholesterol biosynthesis.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>One matching placebo daily
Placebo: A substance that has no therapeutic effect, and will be used as a control in testing the study agent.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Native T1 as Measured by CMRI</title>
          <population>As accrual fell well below target, change in native T1 as measured by CMRI was not calculated.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Post Contrast T1 as Measured by CMRI</title>
        <time_frame>Baseline to 12 months of follow-up</time_frame>
        <population>As accrual fell well below target, change in post contrast T1 as measured by CMRI was not calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Agent</title>
            <description>One atorvastatin 20 mg oral capsule per day
Atorvastatin: Atorvastatin calcium, a synthetic lipid-lowering agent, is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, an early and rate-limiting step in cholesterol biosynthesis.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>One matching placebo daily
Placebo: A substance that has no therapeutic effect, and will be used as a control in testing the study agent.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Post Contrast T1 as Measured by CMRI</title>
          <population>As accrual fell well below target, change in post contrast T1 as measured by CMRI was not calculated.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Extracellular Volume as Measured by CMRI</title>
        <time_frame>Baseline to 12 months of follow-up</time_frame>
        <population>As accrual fell well below target, change in extracellular volume as measured by CMRI was not calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Agent</title>
            <description>One atorvastatin 20 mg oral capsule per day
Atorvastatin: Atorvastatin calcium, a synthetic lipid-lowering agent, is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, an early and rate-limiting step in cholesterol biosynthesis.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>One matching placebo daily
Placebo: A substance that has no therapeutic effect, and will be used as a control in testing the study agent.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Extracellular Volume as Measured by CMRI</title>
          <population>As accrual fell well below target, change in extracellular volume as measured by CMRI was not calculated.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Native T2 as Measured by CMRI</title>
        <time_frame>Baseline to 12 months of follow-up</time_frame>
        <population>As accrual fell well below target, change in native T2 as measured by CMRI was not calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Agent</title>
            <description>One atorvastatin 20 mg oral capsule per day
Atorvastatin: Atorvastatin calcium, a synthetic lipid-lowering agent, is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, an early and rate-limiting step in cholesterol biosynthesis.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>One matching placebo daily
Placebo: A substance that has no therapeutic effect, and will be used as a control in testing the study agent.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Native T2 as Measured by CMRI</title>
          <population>As accrual fell well below target, change in native T2 as measured by CMRI was not calculated.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected over the 12-month intervention period and within 30 days of the last administration of the study drug.</time_frame>
      <desc>Regular investigator assessment, regular laboratory testing, self-reporting.</desc>
      <group_list>
        <group group_id="E1">
          <title>Study Agent</title>
          <description>One atorvastatin 20 mg oral capsule per day
Atorvastatin: Atorvastatin calcium, a synthetic lipid-lowering agent, is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, an early and rate-limiting step in cholesterol biosynthesis.</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>One matching placebo daily
Placebo: A substance that has no therapeutic effect, and will be used as a control in testing the study agent.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>abdominal cramping</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>vitamin D deficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>abdominal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>osteoporosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>neuralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>mood changes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>hot flashes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Accrual fell well below target. Two subjects were randomized to the study and one subject completed the study. Outcome measures were not analyzed due to insufficient accrual.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Marc Goodman, PhD</name_or_title>
      <organization>Cedars-Sinai Medical Center</organization>
      <phone>310-423-6188</phone>
      <email>Marc.Goodman@cshs.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

